Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Atrasentan, an endothelin receptor antagonist, showed clinically significant albuminuria reduction with minimal signs of fluid retention in phase II trials. We evaluated whether plasma exposure was associated with long‐term outcomes for kidney protection and heart failure in the phase III SONAR tria...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Pharmacol Ther
Κύριοι συγγραφείς: Koomen, Jeroen V., Stevens, Jasper, Bakris, George, Correa‐Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald E., Makino, Hirofumi, McMurray, John J. V., Parving, Hans‐Henrik, Perkovic, Vlado, Tobe, Sheldon W., de Zeeuw, Dick, Heerspink, Hiddo J. L.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2021
Θέματα:
Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246733/
https://ncbi.nlm.nih.gov/pubmed/33338269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.2143
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια